(AEON) AEON Biopharma - Ratings and Ratios
Exchange: NYSE MKT • Country: United States • Currency: USD • Type: Common Stock • ISIN: US00775E1029
AEON: Botulinum Toxins, PrabotulinumtoxinA, Injections
AEON Biopharma, Inc. (NYSE MKT:AEON) is a clinical-stage biopharmaceutical company specializing in the development of botulinum toxins for therapeutic applications. The companys lead product candidate, ABP-450 (prabotulinumtoxinA), is a novel botulinum toxin type A injection designed to address debilitating medical conditions. ABP-450 has completed a Phase 2 study for cervical dystonia, demonstrating promising efficacy and safety. Additionally, it is currently under evaluation in an ongoing Phase 2 study for both chronic and episodic migraine, targeting a significant unmet need in neurology. Beyond these indications, AEON is exploring ABP-450s potential in treating gastroparesis and posttraumatic stress disorder (PTSD), expanding its pipeline into gastrointestinal and psychiatric disorders. The companys strategic focus on botulinum toxins leverages the well-established safety profile of these agents while aiming to improve upon existing treatments through enhanced potency, duration of effect, and targeted delivery. Headquartered in Irvine, California, AEON Biopharma is committed to advancing its pipeline to address a range of high-burden conditions. Web URL: https://www.aeonbiopharma.com
Based on the provided technical and fundamental data, AEON Biopharmas stock is expected to face significant headwinds in the next three months. The stock is currently trading below its 20-day, 50-day, and 200-day moving averages, indicating a bearish trend. The average volume of 5.46 million shares suggests moderate liquidity, but the low ATR of 0.13 indicates limited price volatility. With a forward P/E of 1.16 and a P/S ratio of 97.16, the stock appears undervalued on a forward earnings basis but overvalued relative to its sales. The companys negative return on equity (-76.48%) raises concerns about profitability. Given these factors, investors should expect continued price pressure and potential volatility, with the stock likely to remain range-bound in the near term. Small-cap biotechnology stocks like AEON are inherently high-risk, and the companys clinical-stage pipeline adds to the uncertainty.
Additional Sources for AEON Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
AEON Stock Overview
Market Cap in USD | 1m |
Sector | Healthcare |
Industry | Biotechnology |
GiC Sub-Industry | Biotechnology |
IPO / Inception | 2021-04-12 |
AEON Stock Ratings
Growth 5y | -73.2% |
Fundamental | -2.07% |
Dividend | 0.0% |
Rel. Strength Industry | -99.9 |
Analysts | 4/5 |
Fair Price Momentum | 0.68 USD |
Fair Price DCF | - |
AEON Dividends
No Dividends PaidAEON Growth Ratios
Growth Correlation 3m | -93% |
Growth Correlation 12m | -94.3% |
Growth Correlation 5y | -69.3% |
CAGR 5y | -88.60% |
CAGR/Max DD 5y | -0.89 |
Sharpe Ratio 12m | -2.13 |
Alpha | -116.16 |
Beta | 1.85 |
Volatility | 428.80% |
Current Volume | 932.2k |
Average Volume 20d | 4323k |
As of March 16, 2025, the stock is trading at USD 0.66 with a total of 932,181 shares traded.
Over the past week, the price has changed by +0.21%, over one month by -92.88%, over three months by -98.59% and over the past year by -99.94%.
Neither. Based on ValueRay Fundamental Analyses, AEON Biopharma is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -2.07 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of AEON as of March 2025 is 0.68. This means that AEON is currently overvalued and has a potential downside of 3.03%.
AEON Biopharma has received a consensus analysts rating of 4.00. Therefor, it is recommend to buy AEON.
- Strong Buy: 0
- Buy: 1
- Hold: 0
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, AEON AEON Biopharma will be worth about 0.7 in March 2026. The stock is currently trading at 0.66. This means that the stock has a potential upside of +10.61%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 360 | 54445.5% |
Analysts Target Price | 5 | 657.6% |
ValueRay Target Price | 0.7 | 10.6% |